- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01591876
Exercise and Vascular Function in Haemodialysis Patients
The Effect of an Intra-dialytic Aerobic Exercise Intervention on Vascular Function in People Undergoing Maintenance Haemodialysis Therapy for Chronic Kidney Disease Stage 5. An Exploratory Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Life expectancies in haemodialysis patients are significantly shorter than the general population due to higher cardiovascular disease risk. This is mediated by higher prevalence of cardiovascular risk factors associated with chronic kidney disease and the haemodialysis procedure. Consequently ageing of the arterial system is accelerated in this condition leading to higher prevalence of arterial plaques and increased arterial stiffness.
Higher physical activity and fitness are associated with lower cardiovascular disease and all-cause mortality in haemodialysis patients and the general population. Moreover, physical inactivity is associated with increased arterial stiffness and plaques which narrow heart arteries. Worryingly the haemodialysis population is on average highly inactive with low fitness.
Current research demonstrates that exercise which improves fitness improves arterial health. Increased bloodflow during exercise stimulates the release of nitric oxide causing arteries to dilate. Regular exercise is believed to lead to beneficial remodelling of arteries and lower arterial stiffness. Exercise is reported to improve arterial function across a range of conditions. However published research regarding the possible benefits of long term aerobic exercise on arterial health in this population is conflicting. Limitations in study design, moderately high participant dropout rates and low statistical power hamper a definitive conclusion. Importantly a gold standard measure of arterial function has not been used in previously published studies.
There is ample evidence that exercise programmes in people on dialysis improve fitness, physical function, and quality of life. It is also clear that a state of higher physical activity and fitness is associated with better arterial function in the general population. It would be advantageous for reasons of health counselling to determine whether the process of improving physical fitness and activity levels may also improve arterial health in haemodialysis patients.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Sean Prescott, MSc
- Phone Number: +447980338486
- Email: sprescott@qmu.ac.uk
Study Locations
-
-
-
Airdrie, United Kingdom, ML6 0JS
- Recruiting
- Monklands Hospital
-
Contact:
- Jamie Traynor, MD
- Phone Number: +44 1236748748
-
Sub-Investigator:
- Jamie Traynor, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Stage 5 CKD patients (GFR <15 mL/min) receiving maintenance haemodialysis therapy
- Male or female
- Aged >18 years
- Written informed consent
Exclusion Criteria:
- Pregnancy
- Unstable cardiovascular conditions
- Recent cerebrovascular event
- Excess inter-dialytic weight gain
- Use of corticosteroids, anabolic therapies,
- Co-morbid catabolic conditions
- Serum potassium regularly >6mmol/L
- Recent pulmonary thromboembolism
- Psychiatric illness including anxiety, mood and untreated eating disorders
- Infection or course of antibiotics within one month of study period.
- Dementia or severe cognitive impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: Progressive muscle relaxation
As well as usual care participants in the control arm will receive instruction in progressive muscle relaxation.
|
This is a sequence of stretching and relaxation of the major muscle groups of the body.
Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions.
Participants in this group are offered the exercise programme at the end of three months.
|
Active Comparator: Aerobic exercise
Intervention -moderate intensity aerobic exercise.
|
Participants in the intervention group will undertake moderate intensity aerobic exercise.
Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions.
Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale.
Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level.
Adherence and training volume is recorded during the intervention period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Brachial artery flow mediated dilatation
Time Frame: Baseline and 12 week follow-up
|
Brachial artery diameter is measured using vascular ultrasound.
A cuff similar to that used for blood pressure is then inflated around the forearm for 5 minutes.
Following cuff release vascular ultrasound is used to measure arterial dilation in response to reactive hyperaemia.
Relative change in diameter provides a measure of endothelial function.
Images are recorded over a period of 4-5 minutes post cuff release.
|
Baseline and 12 week follow-up
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Aortic pulse wave velocity
Time Frame: Baseline and three month follow-up
|
Aortic pulse wave velocity is measured using a Vicorder (Skidmore Medical, Bristol UK).
Briefly the Vicorder measures the time taken for a pulse wave to travel between a pressure cuff located on the carotid artery and another at the site of the femoral artery.
The calculated velocity of the pulse wave is a measure of central arterial stiffness.
|
Baseline and three month follow-up
|
Maximal aerobic power
Time Frame: Baseline and three months
|
Peak aerobic power is assessed using a graded exercise test with respiratory gas analysis.
An Astrand protocol will be used with cycle ergometry.
Participants continue until volitional exhaustion or the test is terminated by the investigator.
An oxygen uptake figure in ml/kg/min is a measure of peak aerobic power (VO2peak)
|
Baseline and three months
|
Timed up-and-go
Time Frame: Baseline and three month follow-up
|
The time taken to stand up from a chair, walk three metres and return is recorded.
This is a functional measure of mobility with a threshold time related to falls and fractures.
|
Baseline and three month follow-up
|
Sit-to-stand 5
Time Frame: Baseline and 3 month follow-up
|
The time taken to stand up from a chair five times without using upper limb assistance is recorded.
This is a surrogate measure of lower limb power with a threshold that is related to balance and risk of falls.
|
Baseline and 3 month follow-up
|
Non exercise questionnaire
Time Frame: Baseline and 3 month follow-up
|
A non-exercise questionnaire utilising anthropometry, gender and self reported physical activity will be used to estimate aerobic fitness.
This method carries minimal burden compared to physical performance tests and is a useful screening tool for health counselling.
|
Baseline and 3 month follow-up
|
Physical activity
Time Frame: Baseline and 3 month follow-up
|
Physical activity over a seven day period will be measured using an Actigraph accelerometer.
The monitor measures body movement as activity counts which may be categorised according to level of intensity using established cut-points.
|
Baseline and 3 month follow-up
|
Kidney Disease Quality of Life Short Form (KDQOL)
Time Frame: Baseline and 3 month follow-up
|
The KDQOL is a self-administered questionnaire designed to measure generic health related quality life as well as condition specific items.
Higher scores indicate better quality of life.
|
Baseline and 3 month follow-up
|
Duke Activity Status Index
Time Frame: Baseline and 3 months
|
This self administered 12 item questionnaire provides a self reported measure of physical capacity.
Higher scores indicate higher fitness and ability to perform activities of daily living.
|
Baseline and 3 months
|
Leicester Uraemic Symptom Scale (LUSS)
Time Frame: Baseline and 3 month follow-up
|
The LUSS provides a measure of condition related symptom burden.
it records the number of symptoms, frequency and their level of intrusiveness.
|
Baseline and 3 month follow-up
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Tom Mercer, Professor, Queen Margaret University
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12/WS/0129
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Kidney Disease Stage 5
-
Heinrich-Heine University, DuesseldorfRecruitingVaccine Response Impaired | Chronic Kidney Disease Stage 5 on Dialysis | Chronic Kidney Disease Stage 5 With TransplantGermany
-
3-C Institute for Social DevelopmentUniversity of North Carolina, Chapel HillCompletedChronic Kidney Diseases | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Pediatric Kidney Disease | Chronic Kidney Disease stage3 | Chronic Kidney Disease Stage V | Chronic Kidney Disease, Stage IV (Severe) | Chronic Kidney Disease Stage 2 | Chronic Kidney Disease, Stage IUnited States
-
University of MichiganTheravance BiopharmaCompletedEnd-Stage Renal Disease | Stage 5 Chronic Kidney DiseaseUnited States
-
Zydus Lifesciences LimitedCompletedAnemia | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4India
-
National University, SingaporeUnknownChronic Kidney Disease Stage 5 | Chronic Kidney Disease Stage 3 | Chronic Kidney Disease Stage 4Singapore
-
ArdelyxAstraZenecaCompletedEnd Stage Renal Disease | ESRD | Chronic Kidney Disease Stage 5United States
-
liberDi Ltd.RecruitingChronic Kidney Disease Stage 5Israel
-
ShireCompletedChronic Kidney Disease, Stage 5United States, Germany, Puerto Rico, United Kingdom
-
National University of SingaporeUnknownStage 5 Chronic Kidney DiseaseSingapore
-
Savient PharmaceuticalsCompletedChronic Kidney Disease Stage 5United States
Clinical Trials on Progressive Muscle relaxation
-
Ataturk UniversityCompletedStress | Anxiety | Nursing Students | Relaxation ProgramTurkey
-
Gazi UniversityCompletedProgressive Muscle Relaxation ExerciseTurkey
-
Ege UniversityCompletedRestless Legs Syndrome
-
Mayo ClinicCompleted
-
Hacettepe UniversityAnkara City Hospital BilkentRecruiting
-
Mardin Artuklu UniversityCompleted
-
Taipei Medical UniversityCompletedAffective Disorders | Psychotic Disorder
-
Federal University of Espirito SantoCompletedDepression | Multiple Sclerosis | Sleep | Stress Psychological
-
Hasan Kalyoncu UniversityNot yet recruiting
-
Chulalongkorn UniversityCompleted